NICE drug wars: Tarceva vs Iressa, Revlimid vs IFN alpha, Botox vs SoC, and others
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is to put Roche's Tarceva (erlotinib) under the microscope as a first-line option for treating adults with epidermal growth factor receptor (EGFR) mutation positive, locally advanced or metastatic non-small-cell lung cancer (NSCLC). The institute has recently put out for consultation a draft appraisal scope for Tarceva, as well as one for Allergan's Botox and three for Celgene's Revlimid.